BioXcel reports Q1 net loss $12.7M; FDA sets Nov 14 PDUFA for at-home IGALMI

BioXcel Therapeutics, Inc.

2026-Q1 EPS reported -$0.54 revenue$206,000

FDA accepted sNDA for IGALMI at-home use in agitation associated with bipolar/schizophrenia; PDUFA date Nov 14, 2026.
Net revenue $206K (up 23% YoY from $168K); net loss $12.7M vs $7.3M in Q1 2025.
Engaged MTS Health Partners to explore strategic options including sale, merger, or collaboration.
Cash and equivalents $17.2M as of Mar 31, 2026; company in compliance with credit covenants.
R&D down to $3.0M from $4.6M due to SERENITY trial completion; SG&A up to $7.2M from $5.7M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.